vs

Side-by-side financial comparison of Primis Financial Corp. (FRST) and Health Catalyst, Inc. (HCAT). Click either name above to swap in a different company.

Health Catalyst, Inc. is the larger business by last-quarter revenue ($74.7M vs $45.6M, roughly 1.6× Primis Financial Corp.). Primis Financial Corp. runs the higher net margin — 16.0% vs -121.9%, a 137.9% gap on every dollar of revenue. Over the past eight quarters, Primis Financial Corp.'s revenue compounded faster (13.0% CAGR vs -0.0%).

Primis Financial Corp is a U.S.-based financial holding company operating full-service banking subsidiaries. It provides a comprehensive range of financial solutions including personal and commercial deposit products, diverse loan facilities, mortgage services, and wealth management support, primarily serving retail and corporate customers across the U.S. mid-Atlantic region.

Catalyst Pharmaceuticals, Inc. is a biopharmaceutical company based in Coral Gables, Florida, United States. The company develops medicines for rare diseases, including the phosphate salt of amifampridine for the treatment of Lambert–Eaton myasthenic syndrome (LEMS). The drug is referred to under the trade name Firdapse, which was approved by the FDA for approved use in children 6 years and older with LEMS in addition to the prior approval for use in adults with LEMS on November 28, 2018. Fir...

FRST vs HCAT — Head-to-Head

Bigger by revenue
HCAT
HCAT
1.6× larger
HCAT
$74.7M
$45.6M
FRST
Higher net margin
FRST
FRST
137.9% more per $
FRST
16.0%
-121.9%
HCAT
Faster 2-yr revenue CAGR
FRST
FRST
Annualised
FRST
13.0%
-0.0%
HCAT

Income Statement — Q1 FY2026 vs Q4 FY2025

Metric
FRST
FRST
HCAT
HCAT
Revenue
$45.6M
$74.7M
Net Profit
$7.3M
$-91.0M
Gross Margin
Operating Margin
-115.3%
Net Margin
16.0%
-121.9%
Revenue YoY
-6.2%
Net Profit YoY
200.0%
-340.3%
EPS (diluted)
$0.30
$-1.29

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
FRST
FRST
HCAT
HCAT
Q1 26
$45.6M
Q4 25
$80.9M
$74.7M
Q3 25
$41.0M
$76.3M
Q2 25
$43.2M
$80.7M
Q1 25
$58.7M
$79.4M
Q4 24
$38.8M
$79.6M
Q3 24
$37.3M
$76.4M
Q2 24
$35.7M
$75.9M
Net Profit
FRST
FRST
HCAT
HCAT
Q1 26
$7.3M
Q4 25
$29.5M
$-91.0M
Q3 25
$6.8M
$-22.2M
Q2 25
$2.4M
$-41.0M
Q1 25
$22.6M
$-23.7M
Q4 24
$-26.2M
$-20.7M
Q3 24
$1.2M
$-14.7M
Q2 24
$3.4M
$-13.5M
Gross Margin
FRST
FRST
HCAT
HCAT
Q1 26
Q4 25
Q3 25
52.6%
Q2 25
Q1 25
Q4 24
Q3 24
47.5%
Q2 24
Operating Margin
FRST
FRST
HCAT
HCAT
Q1 26
Q4 25
44.8%
-115.3%
Q3 25
21.3%
-22.9%
Q2 25
6.9%
-46.0%
Q1 25
41.9%
-25.4%
Q4 24
-123.0%
-22.0%
Q3 24
-3.1%
-17.9%
Q2 24
7.8%
-20.8%
Net Margin
FRST
FRST
HCAT
HCAT
Q1 26
16.0%
Q4 25
36.5%
-121.9%
Q3 25
16.7%
-29.1%
Q2 25
5.6%
-50.8%
Q1 25
38.6%
-29.9%
Q4 24
-100.3%
-26.0%
Q3 24
3.3%
-19.3%
Q2 24
9.6%
-17.8%
EPS (diluted)
FRST
FRST
HCAT
HCAT
Q1 26
$0.30
Q4 25
$1.19
$-1.29
Q3 25
$0.28
$-0.32
Q2 25
$0.10
$-0.59
Q1 25
$0.92
$-0.35
Q4 24
$-0.95
$-0.33
Q3 24
$0.05
$-0.24
Q2 24
$0.14
$-0.23

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
FRST
FRST
HCAT
HCAT
Cash + ST InvestmentsLiquidity on hand
$159.9M
$95.7M
Total DebtLower is stronger
$153.3M
Stockholders' EquityBook value
$427.2M
$245.8M
Total Assets
$4.3B
$502.6M
Debt / EquityLower = less leverage
0.62×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
FRST
FRST
HCAT
HCAT
Q1 26
$159.9M
Q4 25
$143.6M
$95.7M
Q3 25
$63.9M
$91.5M
Q2 25
$94.1M
$97.3M
Q1 25
$57.0M
$342.0M
Q4 24
$64.5M
$392.0M
Q3 24
$77.3M
$387.3M
Q2 24
$66.6M
$308.3M
Total Debt
FRST
FRST
HCAT
HCAT
Q1 26
Q4 25
$153.3M
Q3 25
$153.1M
Q2 25
$153.0M
Q1 25
$382.9M
Q4 24
$382.4M
Q3 24
$345.0M
Q2 24
Stockholders' Equity
FRST
FRST
HCAT
HCAT
Q1 26
$427.2M
Q4 25
$422.9M
$245.8M
Q3 25
$382.2M
$331.9M
Q2 25
$376.4M
$347.5M
Q1 25
$375.6M
$376.8M
Q4 24
$351.8M
$365.2M
Q3 24
$381.0M
$355.0M
Q2 24
$376.0M
$357.0M
Total Assets
FRST
FRST
HCAT
HCAT
Q1 26
$4.3B
Q4 25
$4.0B
$502.6M
Q3 25
$4.0B
$587.1M
Q2 25
$3.9B
$616.2M
Q1 25
$3.7B
$891.5M
Q4 24
$3.7B
$858.9M
Q3 24
$4.0B
$813.0M
Q2 24
$4.0B
$691.7M
Debt / Equity
FRST
FRST
HCAT
HCAT
Q1 26
Q4 25
0.62×
Q3 25
0.46×
Q2 25
0.44×
Q1 25
1.02×
Q4 24
1.05×
Q3 24
0.97×
Q2 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
FRST
FRST
HCAT
HCAT
Operating Cash FlowLast quarter
$9.9M
Free Cash FlowOCF − Capex
$9.6M
FCF MarginFCF / Revenue
12.9%
Capex IntensityCapex / Revenue
0.4%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-697.0K

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
FRST
FRST
HCAT
HCAT
Q1 26
Q4 25
$10.8M
$9.9M
Q3 25
$-11.4M
$-464.0K
Q2 25
$-41.0M
$-9.0M
Q1 25
$34.4M
$280.0K
Q4 24
$19.5M
$-3.5M
Q3 24
$6.1M
$6.2M
Q2 24
$52.3M
$1.6M
Free Cash Flow
FRST
FRST
HCAT
HCAT
Q1 26
Q4 25
$9.0M
$9.6M
Q3 25
$-719.0K
Q2 25
$-9.2M
Q1 25
$-390.0K
Q4 24
$18.3M
$-3.9M
Q3 24
$5.5M
Q2 24
$1.3M
FCF Margin
FRST
FRST
HCAT
HCAT
Q1 26
Q4 25
11.2%
12.9%
Q3 25
-0.9%
Q2 25
-11.4%
Q1 25
-0.5%
Q4 24
47.3%
-4.9%
Q3 24
7.2%
Q2 24
1.7%
Capex Intensity
FRST
FRST
HCAT
HCAT
Q1 26
Q4 25
2.1%
0.4%
Q3 25
0.3%
Q2 25
0.3%
Q1 25
0.8%
Q4 24
3.1%
0.5%
Q3 24
0.0%
0.9%
Q2 24
0.0%
0.4%
Cash Conversion
FRST
FRST
HCAT
HCAT
Q1 26
Q4 25
0.36×
Q3 25
-1.67×
Q2 25
-16.82×
Q1 25
1.52×
Q4 24
Q3 24
4.93×
Q2 24
15.21×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

FRST
FRST

Net Interest Income$32.1M70%
Noninterest Income$13.6M30%

HCAT
HCAT

Recurring Technology$51.9M69%
Professional Services$22.8M31%

Related Comparisons